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Abstract
Background: In the HAART era, the incidence of HIV-associated non-Hodgkin lymphoma (NHL) is decreasing. We
describe cases of NHL among patients with multi-class antiretroviral resistance diagnosed rapidly after initiating
newer-class antiretrovirals, and examine the immunologic and virologic factors associated with potential IRIS-
mediated NHL.
Methods: During December 2006 to January 2008, eligible HIV-infected patients from two affiliated clinics accessed
Expanded Access Program antiretrovirals of raltegravir, etravirine, and/or maraviroc with optimized background. A
NHL case was defined as a pathologically-confirmed tissue diagnosis in a patient without prior NHL developing
symptoms after starting newer-class antiretrovirals. Mean change in CD4 and log10 VL in NHL cases compared to
controls was analyzed at week 12, a time point at which values were collected among all cases.
Results: Five cases occurred among 78 patients (mean incidence = 64.1/1000 patient-years). All cases received
raltegravir and one received etravirine. Median symptom onset from newer-class antiretroviral initiation was
5 weeks. At baseline, the median CD4 and VL for NHL cases (n = 5) versus controls (n = 73) were 44 vs.117 cells/
mm3 (p = 0.09) and 5.2 vs. 4.2 log10 (p = 0.06), respectively. The mean increase in CD4 at week 12 in NHL cases
compared to controls was 13 (n = 5) vs. 74 (n = 50)(p = 0.284). Mean VL log10 reduction in NHL cases versus
controls at week 12 was 2.79 (n = 5) vs. 1.94 (n = 50)(p = 0.045).
Conclusions: An unexpectedly high rate of NHL was detected among treatment-experienced patients achieving a
high level of virologic response with newer-class antiretrovirals. We observed trends toward lower baseline CD4
and higher baseline VL in NHL cases, with a significantly greater decline in VL among cases by 12 weeks. HIV-
related NHL can occur in the setting of immune reconstitution. Potential immunologic, virologic, and newer-class
antiretroviral-specific factors associated with rapid development of NHL warrants further investigation.
Introduction
Non-Hodgkin lymphoma (NHL) is an HIV-associated
malignancy that has been decreasing in incidence, ran-
ging from approximately 1 to 3 cases per 1,000 person-
years, among HIV-infected persons in the highly active
antiretroviral therapy (HAART) era, representing a
roughly10-fold reductionf r o mt h ep r e - H A A R Te r a
[1-9]. The main determinants for increased risk of NHL
in HIV-infected persons are prolonged immunosuppres-
sion with T-cell depletion and uncontrolled plasma HIV
viremia [3,4,10-15]. Epstein-Barr virus (EBV) activation
has been linked to B-cell stimulation in the most com-
mon types of HIV-related NHL, diffuse large cell non-
Hodgkin and Burkitt lymphomas [10,16,17]. Upon
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immunodeficiency, immune restoration may be
adversely affected by a dysregulation of pathogen-speci-
fic immune responses, commonly referred to as immune
reconstitution inflammatory syndrome (IRIS) [18,19].
B-cell NHL as a manifestation of IRIS is poorly charac-
terized and has rarely been reported; it has mainly been
recognized as NHL recurrence in patients with a pre-
vious diagnosis of NHL [20-22].
During 2006 to 2008, an unprecedented number of
new antiretrovirals became available through expanded
access programs (EAP) for treatment-experienced HIV-
infected patients with multiple-class drug resistance. We
report cases of B-cell NHL among patients without
prior history of NHL diagnosed rapidly after initiating
newer class antiretrovirals during the EAP study period,
and examine the immunologic and virologic factors
associated with potential IRIS-mediated NHL.
Methods
Two affiliated HIV clinics in Chicago, IL participated in
open-label EAP trials for etravirine (TMC125-C214), ral-
tegravir (MK0518-023), and maraviroc (A4001050) dur-
ing December 2006 to January 2008. Protocols were
approved by the John H. Stroger Jr. Hospital of Cook
County and Rush University Medical Center institu-
tional review board (IRB), and all subjects provided writ-
ten informed consent prior to enrollment to each EAP.
During the baseline visit, physical exam and review of
systems (an inventory of systems-based symptoms) were
performed and newer-class antiretrovirals were distribu-
ted with optimized background regimens. The last CD4
count and HIV RNA viral load (VL) measured in a sub-
ject before regimens including newer-class agents were
initiated were considered baseline values. Subjects were
evaluated for adverse events, CD4 and HIV RNA VL at
weeks 4 (± 1 week) and 12 (± 2 weeks), and then every
12 weeks through 48 weeks as available.
We compared patients without NHL (controls) with
those who developed NHL (cases) in a retrospective
cohort study among subjects enrolled upon initiation of
newer-class antiretrovirals. A NHL case was defined as a
tissue diagnosis confirmed by pathologic examination
and immunohistochemical staining in a patient without
prior history of NHL, with symptoms recorded after
starting newer-class regimens during the EAP study per-
iod. All NHL cases were reported as serious adverse
events to the EAP sponsor. Differences in demographic
information, including median age and sex, and baseline
median values of CD4 and log10 VL, were calculated
using a Mann Whitney test. Mean change in CD4 and
log10 VL in NHL cases compared to controls at week 12,
a time point at which values were collected among all
cases, was analyzed using a 2-sided t test. The log10 of an
undetectable HIV RNA VL (< 75 copies/ml) was set at
1.90, and at 5.70 for a VL > 500,000. Risk ratios and
related p-values for NHL diagnoses associated with cur-
rent antiretroviral use, including nucleos(t)ide reverse
transcriptase inhibitor class, raltegravir, etravirine, mara-
viroc, darunavir/ritonavir, and enfuvirtide, were calcu-
lated using a Mantel-Haentzel c
2 test, or Fisher’s exact
test where appropriate. The a of statistical significance
was < 0.05. All analysis was performed using SPSS ver-
sion 11.5 for Windows (SPSS Inc, Chicago, IL).
Results
There were 5 new NHL cases identified among 78 total
subjects enrolled during the EAP study period (mean
incidence = 64.1/1000 patient-years) (Table 1). Two of
these patients with NHL were screened for the raltegra-
vir protocol MK 0518-023, though received raltegravir
after the protocol closed in October 2007 upon FDA
licensure. The median duration from HIV diagnosis to
onset of NHL illness was 16 years. The median age of
both cases and controls was 46 years (p = 1.0). Four of
5 cases were male (80%) compared to males comprising
83% (n = 60) of controls (p = 1.0). The median time
from starting newer-class regimens to NHL symptom
onset was 5 weeks.
At baseline, the median CD4 and VL for NHL cases
(n = 5) versus controls (n = 73) were 44 vs.117 cells/
mm3 (p = 0.09) and 5.2 vs. 4.2 log10 (p = 0.06), respec-
tively. The mean increase in CD4 at week 12 in NHL
cases compared to controls was 13 (n = 5) vs. 74 (n = 50)
(p = 0.284) (figure 1). Mean VL log10 r e d u c t i o ni nN H L
cases versus controls at week 12 was 2.79 (n = 5) vs. 1.94
(n = 50)(p = 0.045) (figure 2). At 12 weeks, 60% (n = 3)
of cases had undetectable VL compared to 64% (n = 47)
of controls (p = 1.0), although the VL for patient 4 was
nearly undetectable by week 12 at 84 copies/ml.
All 5 NHL cases received raltegravir. One NHL case
received etravirine and no cases received maraviroc.
There were no statistically significant associations
between receipt of specific antiretrovirals and new NHL
diagnosis (Table 2).
Discussion
An unexpectedly high incidence of NHL, greater than 20-
fold higher than currently observed in large cohort regis-
tries, was detected among treatment-experienced patients
with HIV achieving high levels of virologic response with
newer-class antiretrovirals. Before initiation of new
HAART regimens, we observed a trend toward lower
baseline CD4 cell counts and higher VLs in NHL cases,
suggesting a higher degree of immunosuppression in these
patients than in patients without NHL. Virologic response
to newer-class HAART regimens was significantly greater
at 12 weeks among all NHL cases, with a majority of these
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Page 2 of 8Table 1 Clinical, immunologic, and virologic characteristics among subjects diagnosed with NHL after starting newer-
class antiretroviral regimens
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age (years) 46 57 47 46 43
Sex Male Male Male Male Female
Race/Ethnicity Black Black Black Hispanic, non-Black Black
Hepatitis B or
hepatitis C
coinfection
No No No No No
Year of HIV
diagnosis
1996 1983 1988 1991 2002
Antiretroviral
regimen before
starting newer-
class HAART
Tenofovir/
emtricitabine,
lopinavir/ritonavir
Tenofovir,
lamivudine,
lopinavir/ritonavir
Tenofovir/emtricitabine,
zidovudine
Emtricitabine, nevirapine,
saquinavir, ritonavir
Zidovudine/lamivudine,
efavirenz
Newer-class
HAART
Regimens
Raltegravir, darunavir,
ritonavir, enfurvitide
Raltegravir,
tenofovir/
emtricitabine,
darunavir, ritonavir
Raltegravir, etravirine,
tenofovir/emtricitabine,
zidovudine
Raltegravir, tenofovir/
emtricitabine, zidovudine,
darunavir, ritonavir
Raltegravir, tenofovir/
emtricitabine, darunavir,
ritonavir
Date of newer-
class HAART
initiation
June 2007 November 2007 July 2007 October 2007 December 2007
Interval
between
newer- class
HAART
initiation and
symptom
onset (weeks)
3.5 3 20 6 5
Symptoms at
onset of NHL
Ataxia, urinary
incontinence
Left upper
extremity
numbness and
weakness, diplopia
Left neck mass Low back pain, weight loss Odonophagia, fever
Baseline CD4 6 128 44 69 27
Week 4 (± 1)
CD4
Not performed Not performed 234 195 Not performed
Week 12 (± 2)
CD4
15 4 250 40 33
Week 24 (± 2)
CD4
Not performed 112 294 Not performed (deceased) Not performed
Baseline HIV
viral load
1,135,366 8,111 > 500,000 156,303 17,767
Week 4 (± 1)
viral load
Not performed Not performed 132 84 Not performed
Week 12 (± 2)
viral load
1,356 Undetectable Undetectable 195 Undetectable
Week 24 (± 2)
viral load
Not performed Undetectable Undetectable Not performed (deceased) Not performed
Imaging
findings
Brain MRI: 2.5 cm
necrotic rim-
enhancing lesion in
the right basal
ganglia with
extensive vasogenic
edema
Brain MRI: two
enhancing
cavernous lesions
abutting the right
and left internal
carotid arteries
Neck CT scan: multiple
enlarged left-sided level II to
V lymph nodes with central
necrosis and peripheral
enhancement,
lymphadenopathy in the left
supraclavicular region
Chest/abdominal/pelvic CT
scan: massive
lymphadenopathy in the
neck, left supraclavicular and
paratracheal regions, bilateral
hilum, retroperitoneum,
paraaortic, peripancreatic,
and retrograstric regions,
extending into the splenic
hilum and left kidney, with
bilateral renal vessels
displaced anteriorly. Multiple
masslike bilateral pulmonary
nodules
Neck CT scan: bilateral
level II
lymphadenopathy and a
6 mm nodule in the left
apex with mild
surrounding
inflammation
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compared to patients without NHL. A striking characteris-
tic in NHL cases was the rapid onset of symptomatic dis-
ease which occurred at a median of 5 weeks after starting
new HAART regimens. Our analysis suggests that the
development of NHL may be attributable to either severe
immunosuppression in these patients or complications
from IRIS.
The degree of immunosuppression in HIV infection
has long been linked with risk of developing NHL
[7,23,24]. In early reports assessing immunologic and vir-
ologic parameters associated with NHL, nadir CD4 count
or low time-weighted mean CD4 count appeared to cor-
relate with a high risk of NHL, which would support
hypotheses that a long-term immunocompromised state
may promote emergence of NHL [3,25]. Contemporary
studies, however, have demonstrated that cumulative
HIV viremia, particularly recent exposure to viremia, and
the latest CD4 count measured before the onset of symp-
tomatic NHL may be the most HIV-specific predictive
factors for NHL oncogenesis [11,12,14,15,24,26,27]. Our
analysis correlates with prior studies documenting low
CD4 counts in patients with virologic failure immediately
before the onset of NHL.
An important feature of our cohort was the finding of
symptomatic NHL occurring in the setting of profound
HIV viral load decline following initiation of HAART.
This phenomenon raises the question of whether the
degree and velocity of virologic response we can now
achieve due to the simultaneous availability of new
agents or possible unique properties of newer-class anti-
retrovirals may have facilitated an abnormal lymphopro-
liferative pathway. Clinically, in the largest cohort study
of IRIS among 180 patients, the intensity of the viral
load decrease within 90 days of starting HAART in anti-
retroviral naïve patients was the primary factor in devel-
oping IRIS. A significant association between CD4 cell
count increase and IRIS was not seen until after
3 months to 9 months of HAART initiation [28]. The
immunopathology of IRIS is believed to be largely
mediated by a provoking antigen. In conditions in which
inflammatory cell infiltration and cellular proliferation
of affected tissues occur, pathogen-specific CD8 T cell
responses and enhanced cytokine production appear to
predominate [29-32]. In our study, EBV was identified
in all NHL cases with adequate tissue for pathology
Table 1 Clinical, immunologic, and virologic characteristics among subjects diagnosed with NHL after starting newer-
class antiretroviral regimens (Continued)
Biopsy site and
specimen
Right medial
temporal brain
biopsy
Left axilla lymph
node excisional
biopsy
Left cervical lymph node
excisional biopsy
Left neck lymph node fine
needle aspirate
Right lateral
oropharyngeal wall
biopsy via larynoscopy
Pathology Diffuse large B-cell
lymphoma
Atypical Burkitt
lymphoma with
translocation (8,14)
Diffuse large B-cell lymphoma Diffuse large B-cell
lymphoma
Plasmablastic large B-
cell lymphoma
EBV in situ
hybridization
Positive Positive Tissue preparation
inadequate
Not performed Positive
Chemotherapy Yes Yes Yes Yes Yes
Outcome Died August 2008 Survived Survived Died March 2008 Survived
Figure 1 CD4 cell count responses in NHL cases and controls
after starting newer-class antiretroviral regimens.
Figure 2 Virologic responses in NHL cases and controls after
starting newer-class antiretroviral regimens.
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primarily by CD8 T cells [33,34]. Loss of EBV-specific
CD8 T cell function has been associated with a decrease
in total CD4 T cells in HIV-positive patients with EBV-
related NHL, suggesting a lack of EBV-specific CD4 T
cell help could accelerate NHL disease progression
[35-41]. Loss of CD4 and CD8 memory T cells directed
against latent EBV antigen (EBV nuclear antigen 1) in
patients with poorly controlled HIV infection may be
important components in progression to EBV-related
NHL. In the Amsterdam Cohort, latent EBV-specific
CD4 and CD8 T cell responses were reestablished, with-
out changes in the EBV viral load, when effective
HAART was taken longitudinally over a median of five
years [42]. HIV-related NHL is characterized by high-
grade tumor growth, and in recent multicenter cohort
analyses incident malignancy has been assigned at ≥30
days from initiation of HAART [26]. In patients with
low CD4+ counts and HIV viremia, which may promote
EBV-infected B cell clonal expansion, the evolution
toward EBV-related NHL may be too advanced to be
modified by EBV-specific cytolytic T cell recovery upon
the initiation of effective HAART. Alternatively, during
an interval with rapid HIV viral decay, as can occur
upon introduction of newer-class antiretroviral regi-
mens, aberrant EBV-specific CD4, CD8, and cytokine
IRIS responses may impact memory B cell stimulation,
which may produce a greater risk for NHL emergence.
There were no distinct antiretrovirals that achieved sta-
tistical significance as a risk factor for developing NHL in
our cohort, although the high rate of receipt of nucleos(t)
ide agents and raltegravir in both groups may preclude
useful comparisons. Raltegravir, however, was the only
antiretroviral taken universally by all patients with NHL
as part of their new HAART regimen. In the licensing
trials for raltegravir in treatment-experienced patients, a
disproportionately higher rate of malignancy had been
reported. NHL was the most common HIV-related
malignancy in these studies [43]. HIV-1 integrase inhibi-
tors specifically inhibit the viral enzyme integrase that
catalyzes strand transfer insertion of proviral DNA into
the host-cell genome [44,45]. HIV-1 integrase inhibitors
have a mechanism of action similar to recombination-
activating genes 1 and 2 (RAG1/2), a recombinase
complex fundamental to V(D)J recombination in the
assemblage of human immunoglobulins, both heavy and
light chains, and T cell receptors, ultimately leading to B
and T cell maturation [46-50]. In vitro studies have
shown HIV-1 integrase inhibitors can interfere with
human DNA cleavage and disintegration activities of
RAG1/2 [51]. Infrequently, RAG 1/2 has been shown to
recognize and bind mistakenly to cryptic DNA sequences
that are unrelated to V(D)J recombination, and these
DNA elements may play a significant role in the develop-
ment of lymphoid tumors [52]. RAG1/2 chromosomal
transposition has also been documented in human T
cells, though it appears to be an uncommon event [53].
Despite its rarity, certain oncogenic chromosomal trans-
locations which can juxtapose immunoglobulin and T
cell receptor enhancers with proto-oncogenes may be the
result of RAG1/2 mediated transposition [54]. In cases
suggestive of IRIS-mediated neoplasm in patients taking
an integrase inhibitor as part of their HAART regimen, it
is possible that any potential perturbations to the RAG1/
2 system, coupled with dysfunctional T cells or enhanced
cytokine responses, may be associated with the develop-
ment of symptomatic malignancy.
Our study had several limitations. The analysis was
prompted by reported adverse events during the EAP
time period, therefore because of the nonrandomized,
observational nature of the cohort, we may not have
accounted for other significant risk factors for newly
recognized NHL beyond HIV immunological and viro-
logic baseline features and response rates to antiretro-
viral agents. NHL may have been present before
patients started the newer-class HAART regimens,
though physical exams and a review of systems that
were obtained on all subjects upon distribution of their
new antiretroviral therapy did not uncover sympto-
matic disease in any of the patients. At the median
time of NHL symptom onset (5 weeks) after initiation
of new HAART regimens, evaluable CD4 count and
viral loads were either not obtained or lower due to
chemotherapy for meaningful analysis in 3 of 5 NHL
cases (Patients 1, 2, and 4); therefore, the implication
that an IRIS possibly contributed to the early diagnosis
of these malignancies is inferred primarily upon the
virologic response kinetics in all cases by week 12.
EBV was not identified in 2 of the 5 patients, though
in both of these cases alternative pathogens were not
isolated and sample limitations of the diagnostic tissue
precluded evaluation for EBV markers. Lastly, the
Table 2 Antiretroviral use and risk ratios for
development of NHL in subjects after starting newer-
class antiretroviral regimens
Antiretroviral NHL cases
(n = 5)
Controls
(n = 73)
Unadjusted
Odds Ratio
95% CI
Nucleos(t)ide
reverse
transcriptase
inhibitors
100% 97% NC (p = 1.0)
Raltegravir 100% 86% NC (p = 1.0)
Etravirine 20% 53% 0.29 0.02-2.0
Maraviroc 0 11% 0
Darunavir/ritonavir 80% 59% 2.8 0.30-26.6
Enfuvirtide 20% 4% 5.8 0.40-69.5
NC: not calculated
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precision in the risk factor analysis.
In view of our results, clinicians should be vigilant in
monitoring highly treatment-experienced patients for
signs and symptoms of NHL as a potential IRIS compli-
cation shortly after starting potent antiretroviral therapy.
Measuring elevations in circulating free immunoglobulin
light chains in serum may be a sensitive marker for pre-
dicting NHL in HIV-infected patients, which may be a
useful screening tool in patients at increased risk for
NHL [55]. Given the similar activity of HIV integrase
inhibitors to the RAG1/2 system, which is critical to B
and T cell maturation, HAART regimens containing
integrase inhibitors merit particular attention and
further investigation as a potential novel mechanism in
the development of possible IRIS-related NHL in
patients with depressed immunity.
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